Please login to the form below

Not currently logged in
Email:
Password:

fistulas

This page shows the latest fistulas news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease. Takeda has chalked up a big win this week after receiving a European licence for Alofisel (darvadstrocel), marking the first ... Alofisel - previously Cx601 - is approved to treat

Latest news

  • The power of pharma businesses to drive social change The power of pharma businesses to drive social change

    estimated 3, 000 new cases of obstetric fistula annually, with the problem particularly prevalent in rural communities. ... We are really proud of what we have been able to achieve with the Fistula Foundation.

  • Takeda offers €520m for stem cell firm TiGenix Takeda offers €520m for stem cell firm TiGenix

    Around a quarter of patients with Crohn’s develop fistulas - abnormal channels connecting the bowel to another organ or the outside surface of the body. ... Perianal fistulas are the most common type but are still fairly rare, with patients currently

  • CHMP backs Europe’s first allogeneic stem cell therapy CHMP backs Europe’s first allogeneic stem cell therapy

    Belgian biotech TiGenix and partner Takeda have had their stem cell therapy for perianal fistulas in Crohn’s disease patients recommended for approval in the EU. ... The most common side effects observed include anal abscess and fistula, as well as

  • TiGenix’s Crohn's fistulas treatment wins orphan drug status TiGenix’s Crohn's fistulas treatment wins orphan drug status

    FDA designation follows positive trial results. Belgian biopharmaceutical group TiGenix is one step closer to getting its first-in-class Crohn’s fistulas disease treatment to the US market following an ... The drug - currently known as Cx601 - could

  • TiGenix cell therapy for Crohn's fistulas shows long-term benefit TiGenix cell therapy for Crohn's fistulas shows long-term benefit

    Belgian biotech TiGenix has racked up another positive result for its Takeda-partnered stem cell therapy for fistulas caused by Crohn's disease. ... Results of the phase III ADMIRE-CD trial show that a single administration of Cx601 - a suspension of

More from news
Approximately 4 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    for local administration for the treatment of complex perianal fistulas in patients with Crohn’s disease.  The companies were already partners having signed a $432m licensing deal in July 2016 for ... Option exercise (2 options). 640. TiGenix/Takeda.

  • Case study: Action on Fistula Case study: Action on Fistula

    fistula through building in-country capacity to recognise, treat and eventually eradicate long-term suffering. ... The programme revealed awareness of fistula is very low, even within the healthcare system.

  • Deal Watch July 2016 Deal Watch July 2016

    cells. The product has been submitted to the EMA following a phase III trial showing safety and efficacy of a single injection in the treatment of complex peri-anal fistulas, and ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment for

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....
COVID-proof: How Teams are Creating Launch Intensity thru Adversity
Now that the game has changed, how are marketers shifting their launch behaviour? We've identified 5 common observations from effective teams....